Clinical Information for Respi GX and Infectious Disease Testing
Innovative Genomics offers a comprehensive menu of tests for a wide range of PGx, infectious disease (including COVID-19), and the list is constantly expanding as we proceed through additional research and approvals.
Respi GxTM utilizes quantitative Real-Time Polymerase
Chain Reaction (qPCR) to rapidly analyze your
patient’s sample in 24 hours. RT-PCR technology
precisely detects the correct pathogens(s) and
identifies antibiotic drug resistance. This allows
providers the ability to prescribe timely and effective
Rapid and accurate solution eliminates guesswork in diagnosing and treating upper respiratory infections
Acute respiratory infection is a significant cause of morbidity and mortality in young, geriatric and immunocompromised patients. Co-infection is also high within these populations and access to advanced technology is essential to detect multiple pathogens at once. False negative test results can lead to a delayed diagnosis and poor clinical outcomes.
Respi GxTM quickly identifies pathogens and detects potential antibiotic resistance, so effective treatment can begin sooner.
Helps improve clinical confidence and decrease patient risks